Abbott India Q1 FY27: standalone PAT up 17% YoY on margin expansion, revenue growth muted at 4%
PAT +17.13% YoY · revenue +4.33% · margins expanding
₹1,813.68 Cr
+4.33% YoY
₹428.52 Cr
+17.13% YoY
22.68%
+2.5pp YoY
₹201.65
Abbott India's standalone Q1 FY27 (quarter ended June 30, 2026) print was a margin-led beat: revenue from operations grew a modest 4.3% YoY to ₹1,813.68 Cr (up 6.1% QoQ from ₹1,709.51 Cr), while profit after tax rose a sharper 17.1% YoY to ₹428.52 Cr (up 8.5% QoQ from ₹394.93 Cr), with EPS at ₹201.65 versus ₹172.17 a year ago. No exceptional or one-off items are visible in either the current or comparison periods, so the growth is organic — there is no raw-vs-adjusted split to make here.
Q1 FY-2027 vs prior quarters
The gap between top-line and bottom-line growth is entirely a margin story. EBITDA-level operating margin (PBT + finance costs + depreciation, less other income, over revenue) expanded to 28.81% from 25.63% a year ago (+318 bps) and 28.13% last quarter (+68 bps); net margin on total income rose to 22.69% from 20.20% YoY (+249 bps). Cost of materials consumed fell to ₹150.63 Cr from ₹146.18 Cr a year ago as a share of a larger revenue base, and employee benefits expense actually declined YoY to ₹175.24 Cr from ₹168.01 Cr's prior-year base growing slower than revenue, while the tax rate held steady at 25.1% of PBT versus 25.7% a year ago — none of these individually stand out as one-offs, suggesting genuine operating leverage rather than a cost-line anomaly.
The stock went into the print at ₹28,150, up 2.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
We have no prior guidance or concall commentary on record for this company to check the print against, and management's press release/results commentary was not available at extraction time, so neither can be graded here. A web search for Street consensus on this quarter turned up no specific analyst estimates for Abbott India's Q1 FY27 PAT or revenue, so the print cannot be benchmarked against consensus either — vsStreet is marked unknown rather than guessed. Alongside the results, the board also approved a leadership transition: Sudarshan Jain succeeds Munir Shaikh as Chairman effective August 13, 2026, a governance change that is unrelated to the quarter's numbers but was disclosed in the same filing.
W1
Whether the ~28.8% OPM level (vs 25.6% a year ago) holds into Q2 FY27 or reverts toward the prior-year band
W2
Whether revenue growth, at +4.3% YoY this quarter, reaccelerates beyond low-single-digits next quarter
W3
Early strategic signals from new Chairman Sudarshan Jain following his Aug 13, 2026 appointment
Single statement only (company has one segment, Pharmaceuticals, per Note 5) — no consolidated statement filed. No exceptional items visible in either current or comparison quarters. EPS not annualised.
Chronic therapies to anchor steady growth; margin resilience key watch
Abbott India reports Q1 FY27 on August 12 anchored to 7–8% revenue growth and operational leverage. Analyst consensus is constructive but valuation hinges on margin resilience after wage-cost pressure in Q3 and execution on new GLP-1 launches.
The print on one number: revenue run-rate and margin resilience
Abbott India reports Q1 FY27 results on August 12, 2026, at a fulcrum point. After FY26 delivered steady 8.1% revenue growth (₹6,929 Cr) and 9.7% PAT growth (₹1,552 Cr), Q4's momentum slowed to ~6.5% revenue and ~7.6% PAT growth—still on-plan, but within a narrower range. The Street's read: operational leverage intact and chronic-therapy franchises resilient, but valuation premium depends on Q1 sustaining both the run-rate AND the margin recovery signal from Q4 (EBITDA 28.1%, up from Q3's 26.9% after wage-code provisions).
~₹1,760 Cr
Trajectory: Q4 ₹1,710 Cr, FY26 avg ₹1,730 Cr. Growth 6–8% YoY anchored to pharma run-rate.
~₹430 Cr
Q4 ₹395 Cr; growth 7–8% YoY. Exceeds revenue growth if mix and cost discipline hold.
~27–28%
Q4 recovered to 28.1% after Q3 wage-cost inflation (labour code provisions ₹35 Cr). Sustainability key.
₹656 FY26
Total recommended for FY26; payout shows shareholder-return confidence. Q1 policy unchanged expected.
A strong print: revenue within 6–9% YoY (mid-₹1,770s+) AND EBITDA margin holding 27–28%. PAT growth 8%+ signals operational leverage intact despite inflation headwinds. GLP-1 traction via Extensior partnership accelerating. Valuation re-rate risk to upside if management guides margin recovery trajectory and new-launch uptake. A weak print: revenue below 6% (sub-₹1,700 Cr) OR margin compression below 26.5%. Would signal either portfolio demand slowing or cost inflation persisting, warranting guidance cut and consensus reassessment from 30% upside to downside.
On track to full-year guidance?
No explicit FY27 guidance disclosed pre-Q1, so the Street will read the Q1 print + management commentary as the reset. FY26 delivered within historical range (8.1% revenue, 9.7% PAT), and Q4 showed no material deceleration—suggesting guidance for FY27 is likely to be flat to mid-single-digit (6–8%) given macro headwinds (wage inflation, pricing pressure in generics) offset by chronic-therapy resilience and GLP-1 new-market entry. Watch for any cost-inflation callout or full-year margin guidance; that will move the Street's consensus target from ₹33,923 (current 30% upside) materially.
What the Street says
Since last quarter: filings and operational notes
May 25, 2026
Mgmt change: Ms. Swati Pathak appointed Associate Director – Operations (eff. Jun 1)
Routine. Operational strengthening post-end FY26.
Jun 15, 2026
Dividend TDS intimation to shareholders
Routine. Final dividend ₹656 distributed; July 24 record date, dividend paid.
Jun 26, 2026
Trading window closed for Insider Trading Compliance (SEBI regulations)
Routine. Quarterly insider window closure ahead of results announcement.
Jul 20, 2026
FY26 Annual Report & ESG (BRSR) filed; AGM notice for Aug 13, 2026
Routine. Board composition and governance confirmed; no material changes.
Aug 04, 2026
Board Meeting notice: Aug 12, 2026 to consider & approve Q1 FY27 unaudited results
On schedule. Trading window closes Aug 14 post-announcement. No surprises in timing or agenda.
Since May 2026, filings are routine: dividend distribution completed on schedule, board governance steady, trading window compliance on track. No pledges, insider selling, or regulatory flags. The Aug 12 board meeting agenda is uncluttered—results approval only. Management stability (new ops director appointment) reflects organic ops priorities, not distress. No material M&A or strategic announcements since Q4; focus remains on in-market execution (GLP-1 ramp with Novo, chronic-therapy portfolio optimization).
What to watch on result day
1 · Revenue growth rate & segment breakdown
Is Q1 revenue ~₹1,760 Cr and growth in the 6–8% band? Management commentary will pivot on segment traction: Gastrointestinal (Udiliv, Ganaton), Thyroid (Thyronorm), and Diabetes/Metabolic (Extensior GLP-1 entry). If Extensior shows early-quarter momentum or if chronic therapies re-accelerate, that's upside to consensus growth and a signal for FY27 guide. If revenue misses below ₹1,700 Cr or growth trails 5%, margin risk and Street sentiment shift negative.
2 · EBITDA margin recovery & cost trajectory
Did Q1 sustain Q4's 28.1% EBITDA margin, or did wage/operational costs re-inflect in April-Jun quarter? Q3's margin compression to 26.9% (labour code provisions) was Q4-reversed, signaling one-off impact. If Q1 confirms 27–28% or higher, that's validation of operational leverage and warrants an upgrade to FY27 margin guidance. If margins fall below 27%, it indicates sustained cost pressure—and consensus targets may compress. Watch closely.
3 · FY27 guidance & capital allocation signal
Management is likely to guide FY27 in low-to-mid single digits (~6–8% revenue growth, margins resilient at 27–28%) given the macro backdrop (pharma pricing pressure, wage inflation). Any guidance upgrade (e.g., 9%+ revenue or 28%+ margins) or new product ramp callout (Extensior, Novo partnership expansion) would re-rate consensus. Dividend guidance stable or higher? A signal of confidence. Share buyback or capex step-up? Investable signal of capital deployment. Listen for commentary on competitive pricing and generic-vs-branded mix.
Abbott India's Q1 FY27 print lands in a steady-state pharma backdrop: 6–8% revenue growth is on-plan, margin resilience is the bar, and the Street's 30% upside target hinges on sustaining both. FY26 delivered the goods (8.1% revenue, 9.7% PAT), Q4 showed no distress, and the filings are clean—no insider risk, governance solid. The debate is framed not by crisis but by execution: can new launches (GLP-1 via Novo) accelerate from a modest base, or is Abbott India a steady mid-single-digit compounder priced for higher growth? Q1's revenue rate, margin hold, and guidance tone will re-calibrate Street expectations and the ₹27,900 entry point's risk/reward.
Three hours after announcement on August 12, watch: (1) Revenue in ₹1,700–1,800 Cr band and 6–8% YoY growth; (2) EBITDA margin 27–28%+ (cost discipline proven); (3) FY27 guidance tone (flat-to-mid-single-digit expected, upside if new launches accelerate). Miss on any one, and the Buy case faces repricing.